BC Innovations | Nov 27, 2017
Distillery Therapeutics


INDICATION: Renal damage Mouse studies suggest 14,15-epoxyeicosatrienoic acid (EET) or inhibition of its catabolic enzyme EPHX2 could help treat acute kidney injury (AKI). In a mouse model of AKI, 14,15-EET decreased kidney injury and increased...
BC Innovations | Sep 10, 2015
Distillery Therapeutics

Therapeutics: Epoxyeicosatrienoic acid (EET)

Hematology INDICATION: Stem cell transplant Zebrafish and mouse studies suggest EETs could enhance engraftment of hematopoietic stem/progenitor cell (HSPC) transplants. Screening of a library of bioactive compounds in a zebrafish-based assay of HSPC engraftment identified...
BC Innovations | Jan 12, 2012
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Solid tumors Epoxyeicosatrienoic acids (EETs) Mouse studies suggest antagonizing EETs could help treat solid cancers. EETs are small molecules produced by arachidonic acid metabolism. In...
BC Innovations | Jan 12, 2012
Targets & Mechanisms

EETing away at metastasis

U.S. researchers have shown that antagonizing epoxyeicosatrienoic acids, a type of fatty acid metabolite, reduces tumor growth and metastasis in mice. 1 The challenge will be finding a dose that has the desired effect without...
Items per page:
1 - 4 of 4